Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/immunosenescence.md — the filesystem corpus, unchanged. Not an edit.
13.5 kB
Revision 1
Revision 2
lines 7–13 → 7–136 unchanged lines not shown
categories: ["longevity", "bodies"]categories: ["longevity", "bodies"]tags: ["aging", "immunity", "thymus", "t cells", "vaccines", "mechanisms", "cytomegalovirus"]tags: ["aging", "immunity", "thymus", "t cells", "vaccines", "mechanisms", "cytomegalovirus"]summary: "The age-related remodelling of the immune system, in which responses to unfamiliar antigens weaken while chronic activation against familiar ones persists."summary: "The age-related remodelling of the immune system, in which responses to unfamiliar antigens weaken while chronic activation against familiar ones persists."updated: "2026-07-28"updated: "2026-10-29"humanEvidence: "Thymic involution, naive T-cell decline, repertoire contraction and weaker vaccine responses are all measured directly in people; every proposal to reverse them has been tested only in mice or in small uncontrolled human studies."humanEvidence: "Thymic involution, naive T-cell decline, repertoire contraction and weaker vaccine responses are all measured directly in people; every proposal to reverse them has been tested only in mice or in small uncontrolled human studies."issues: ["The innate arm gets one paragraph; monocyte and NK-cell changes deserve their own treatment."]issues: ["The innate arm gets one paragraph; monocyte and NK-cell changes deserve their own treatment."]------lines 27–86 → 27–8613 unchanged lines not shown
}}`````` **Immunosenescence** is the set of changes that accumulate in the immune system with age: a shrinking capacity to respond to antigens the body has not met before, alongside persistent low-grade activation against antigens it has. It is the immune half of biological aging, and it accounts for a substantial part of the mortality gradient with age: infection kills disproportionately in the old, latent viruses reactivate, and immune control of transformed cells is one of the defences against [[cancer]] that weakens.**Immunosenescence** is the set of changes that accumulate in the immune system with age: a shrinking capacity to respond to antigens the body has not met before, alongside persistent low-grade activation against antigens it has. It is the immune component of biological aging and accounts for a substantial part of the rise in mortality with age. Infection kills disproportionately in the old, latent viruses reactivate, and immune control of transformed cells, one of the body's defences against [[cancer]], weakens. ## What changes## What changes The thymus, where T cells are selected and licensed, begins involuting in childhood and is largely replaced by fat by middle age. Nothing else in the body loses so much of an organ so early with so little clinical notice, and the consequence is that the supply of new naive T cells falls steeply while the existing pool must be maintained by division rather than replacement.The thymus, where T cells are selected and licensed, begins involuting in childhood and is largely replaced by fat by middle age. No other organ loses so much of itself so early with so little clinical notice. As it shrinks, the supply of new naive T cells falls steeply, and the existing pool has to be maintained by division rather than replacement. The result is a compositional shift. Naive T cells decline, memory and terminally differentiated effector cells expand, and the diversity of the T-cell receptor repertoire contracts. Deep sequencing of receptor repertoires in donors from childhood to old age found diversity tracking the naive T-cell fraction, which fell roughly linearly to about the age of 70.[^britanova2014] A narrower repertoire is a narrower set of things that can be recognised, which is the mechanistic link between an aged immune system and a novel pathogen.The composition of the T-cell pool shifts as a result. Naive T cells decline, memory and terminally differentiated effector cells expand, and the diversity of the T-cell receptor repertoire contracts. Deep sequencing of receptor repertoires in donors from childhood to old age found diversity tracking the naive T-cell fraction, which fell roughly linearly to about the age of 70.[^britanova2014] A narrower repertoire can recognise a narrower set of antigens, and that is the mechanistic link between an aged immune system and poor defence against a novel pathogen. The B-cell compartment shifts similarly, with reduced output of new naive B cells and less effective germinal-centre reactions, so antibody responses to new antigens are lower and less durable. Innate immunity changes rather than simply weakening: neutrophil and macrophage function declines while baseline inflammatory signalling rises, the process described under [[inflammaging]]. The two are usually treated together because the [[hallmarks-of-aging|2023 revision of the hallmarks]] added chronic inflammation as a hallmark in its own right, and because senescent cells, which accumulate through the mechanism set out in [[cellular-senescence]], secrete much of the signal involved. Falling output from the haematopoietic compartment is the same phenomenon described under [[stem-cell-exhaustion]], seen from the immune side.The B-cell compartment shifts similarly, with reduced output of new naive B cells and less effective germinal-centre reactions, so antibody responses to new antigens are lower and less durable. Innate immunity changes in more than one direction. Neutrophil and macrophage function declines while baseline inflammatory signalling rises, the process described under [[inflammaging]]. Immunosenescence and inflammaging are usually treated together because the [[hallmarks-of-aging|2023 revision of the hallmarks]] added chronic inflammation as a hallmark in its own right, and because senescent cells, which accumulate through the mechanism set out in [[cellular-senescence]], secrete much of the signal involved. Falling output from the haematopoietic compartment is the immune-side view of the decline described under [[stem-cell-exhaustion]]. ## Cytomegalovirus and the immune risk phenotype## Cytomegalovirus and the immune risk phenotype Most of the world's population carries cytomegalovirus for life, and controlling it consumes a disproportionate share of the T-cell compartment. In some older people, virus-specific clones occupy a large fraction of the entire CD8 pool.Most of the world's population carries cytomegalovirus for life, and keeping it in check takes up a disproportionate share of the T-cell compartment. In some older people, virus-specific clones occupy a large fraction of the entire CD8 pool. Swedish longitudinal studies of octogenarians and nonagenarians identified a cluster of markers that predicted death within two to six years: an inverted CD4/CD8 ratio, poor T-cell proliferative response, and cytomegalovirus seropositivity. The cluster was named the immune risk phenotype and is the closest thing the field has to a validated prognostic immune signature.[^wikby2005] The same research group later reported that individuals who survived to 100 did not show the profile, which is consistent either with the phenotype being a cause of death or with it being a marker of people already failing.Swedish longitudinal studies of octogenarians and nonagenarians identified a cluster of markers that predicted death within two to six years: an inverted CD4/CD8 ratio, poor T-cell proliferative response, and cytomegalovirus seropositivity. The cluster was named the immune risk phenotype, and it is the closest the field has come to a validated prognostic immune signature.[^wikby2005] The same research group later reported that people who survived to 100 did not show the profile. That finding fits two readings: the phenotype may be a cause of death, or it may mark people who are already failing. > [!debate] Decline or remodelling> [!debate] Decline or remodelling> The word "immunosenescence" implies degeneration, and the field is not unanimous that this is the right description. On the alternative reading the aged immune system is remodelled rather than broken: it is optimised for the antigens it has already met, at the cost of the ones it has not, which is a reasonable allocation for an organism past reproduction. Cytomegalovirus is the sharpest version of the argument. It correlates with mortality in Swedish cohorts and does not in some other populations, which suggests its effect depends on context rather than being a fixed cost.> The word "immunosenescence" implies degeneration, and the field is not unanimous that this is the right description. On the alternative reading the aged immune system has been remodelled, not broken. It is optimised for the antigens it has already met at the expense of those it has not, a reasonable allocation for an organism past reproduction. Cytomegalovirus gives the argument its sharpest form: the virus correlates with mortality in Swedish cohorts but not in some other populations, which suggests its effect depends on context and is not a fixed cost. ## Measurement## Measurement There is no accepted assay for immune age, and this is the field's practical bottleneck. Two approaches have been taken.There is no accepted assay for immune age, and the lack of one is the field's practical bottleneck. Researchers have tried two approaches. The first builds composite scores from immune-cell phenotyping. A nine-year longitudinal study of healthy adults produced a trajectory-based metric, IMM-AGE, that predicted all-cause mortality in an independent cohort after adjustment for established risk factors, and that tracked immune status better than chronological age.[^alpert2019] Composite scores built from DNA methylation and from circulating inflammatory proteins are parallel efforts in the same direction, and share the interpretive difficulty set out under [[epigenetic-clock|epigenetic clocks]]: a score that predicts mortality is not thereby a measure of the process that causes it.The first builds composite scores from immune-cell phenotyping. A nine-year longitudinal study of healthy adults produced a trajectory-based metric, IMM-AGE, that predicted all-cause mortality in an independent cohort after adjustment for established risk factors, and that tracked immune status better than chronological age.[^alpert2019] Composite scores built from DNA methylation and from circulating inflammatory proteins pursue the same goal. They share the interpretive difficulty set out under [[epigenetic-clock|epigenetic clocks]]: a score can predict mortality without measuring the process that causes it. The second uses function rather than composition, and the standard functional readout is vaccine response. A quantitative review of thirty-one studies found substantially lower rates of seroconversion and seroprotection after influenza vaccination in older adults than in younger ones across all three vaccine components.[^goodwin2006] Vaccine response has the advantage of measuring what actually matters and the disadvantage of being an indirect and noisy measure of the underlying state. Neither approach has been accepted by a regulator as a surrogate endpoint, which is the general problem set out under [[aging-biomarkers]].The second measures function instead of composition, usually through vaccine response. A quantitative review of thirty-one studies found substantially lower rates of seroconversion and seroprotection after influenza vaccination in older adults than in younger ones across all three vaccine components.[^goodwin2006] Vaccine response measures an outcome that matters clinically, but it is an indirect and noisy guide to the underlying state. Neither approach has been accepted by a regulator as a surrogate endpoint, which is the general problem set out under [[aging-biomarkers]]. ## Consequences## Consequences The clearest is infection. Age-specific mortality from respiratory infection rises steeply and roughly log-linearly through later life, a gradient that was measured with unusual precision during the COVID-19 pandemic and that held across countries with very different health systems.[^odriscoll2021] That gradient is the reason [[engineered-pandemics|pandemic risk]] and longevity are not separate subjects.Infection is the clearest consequence. Age-specific mortality from respiratory infection rises steeply and roughly log-linearly through later life, a gradient that was measured with unusual precision during the COVID-19 pandemic and that held across countries with very different health systems.[^odriscoll2021] Because of that gradient, [[engineered-pandemics|pandemic risk]] and longevity overlap as subjects. Reactivation of latent viruses is the second. Herpes zoster is the visible case: the virus is controlled by cell-mediated immunity that declines with age, and its reactivation rate rises accordingly.Reactivation of latent viruses is the second. Herpes zoster is the visible case: cell-mediated immunity keeps the virus in check, that immunity declines with age, and the reactivation rate rises accordingly. The third is [[cancer|tumour]] surveillance. Immune control of transformed cells is real, as checkpoint blockade demonstrated by removing a brake on it, and a declining capacity to exercise that control is one proposed contributor to the steep rise in cancer incidence with age. The contribution has not been quantified in humans, and the age-incidence curve is adequately explained by mutation accumulation alone, so this remains a plausible mechanism rather than a measured one.The third is [[cancer|tumour]] surveillance. Immune control of transformed cells is real; checkpoint blockade demonstrated it by removing a brake on that control. A declining capacity to exercise it is one proposed contributor to the steep rise in cancer incidence with age. The contribution has not been quantified in humans, and mutation accumulation alone adequately explains the age-incidence curve, so the mechanism is plausible but unmeasured. ## Interventions with evidence in people## Interventions with evidence in people Vaccine formulation is where the field has delivered. High-dose influenza vaccine was more efficacious than standard dose in a randomised trial in adults 65 and over.[^diazgranados2014] The adjuvanted recombinant zoster vaccine reached efficacy above 90% against shingles in adults over 50, far exceeding the live-attenuated vaccine it replaced.[^lal2015] Neither reverses immunosenescence. Both work around it by presenting more antigen or better adjuvant to a system that responds poorly to less.Vaccine formulation is where the field has produced results in people. High-dose influenza vaccine was more efficacious than standard dose in a randomised trial in adults 65 and over.[^diazgranados2014] The adjuvanted recombinant zoster vaccine reached efficacy above 90% against shingles in adults over 50, far exceeding the live-attenuated vaccine it replaced.[^lal2015] Neither vaccine reverses immunosenescence. Both work around it, giving more antigen or a better adjuvant to a system that responds poorly to less. Drug intervention has one suggestive human result. A randomised trial of low-dose mTOR inhibitors in older adults reported improved influenza vaccination response, upregulated antiviral gene expression, and fewer self-reported respiratory infections over the following year.[^mannick2018] The compound was later taken into a larger trial that did not meet its primary endpoint, so the result stands as the most interesting human signal in geroscience and not as a demonstrated therapy. It is the main reason [[rapamycin]] is discussed as an immune-restoring agent rather than only as an immunosuppressant.Drug intervention has one suggestive human result. A randomised trial of low-dose mTOR inhibitors in older adults reported improved influenza vaccination response, upregulated antiviral gene expression, and fewer self-reported respiratory infections over the following year.[^mannick2018] A larger trial of the compound later missed its primary endpoint, so the result stands as the most interesting human signal in geroscience, not a demonstrated therapy. It is the main reason [[rapamycin]] is discussed as an immune-restoring agent rather than only as an immunosuppressant. [[exercise-and-aging|Exercise]] is associated with better vaccine responses and lower infection mortality in observational data, with the causal direction hard to establish in a population where illness reduces activity.[[exercise-and-aging|Exercise]] is associated with better vaccine responses and lower infection mortality in observational data, with the causal direction hard to establish in a population where illness reduces activity. ## Rejuvenation proposals## Rejuvenation proposals Thymic regeneration is the most direct approach. A small uncontrolled study combining growth hormone with two diabetes drugs reported regrowth of thymic tissue on imaging in nine men, along with a reversal of epigenetic clock readings that attracted more attention than the immune data.[^fahy2019] Nine participants with no control arm cannot establish an effect, and the follow-up study has not reported an outcome that changes that.Thymic regeneration is the most direct approach. A small, uncontrolled study combining growth hormone with two diabetes drugs reported regrowth of thymic tissue on imaging in nine men, along with a reversal of epigenetic clock readings that attracted more attention than the immune data.[^fahy2019] Nine participants with no control arm cannot establish an effect, and the follow-up study has not reported an outcome that changes that. Other routes are earlier. Engineering thymic tissue is one of the objectives of [[tissue-engineering]] work, and allogeneic cultured thymus tissue is already approved for children born without the organ. Rejuvenating haematopoietic stem cells by [[partial-reprogramming|transient reprogramming]] is under investigation at companies including [[newlimit]], entirely in cells and mice so far. Clearing senescent T cells with [[senolytics]] has a rationale and no human efficacy data. Immunity is one of the three functional domains scored by the [[xprize-healthspan]] competition, which is a useful forcing function precisely because the field cannot yet agree what to measure.Other routes are earlier. Engineering thymic tissue is one of the objectives of [[tissue-engineering]] work, and allogeneic cultured thymus tissue is already approved for children born without the organ. Rejuvenating haematopoietic stem cells by [[partial-reprogramming|transient reprogramming]] is under investigation at companies including [[newlimit]], entirely in cells and mice so far. Clearing senescent T cells with [[senolytics]] has a rationale but no human efficacy data. Immunity is one of the three functional domains scored by the [[xprize-healthspan]] competition, which forces the question of measurement on a field that cannot yet agree what to measure. ## Open problems## Open problems Whether immunosenescence is a driver of aging or one of its outputs is unsettled, and the question is not merely academic: it determines whether restoring immune function would extend [[healthspan]] broadly or only reduce infection deaths. The [[geroscience-hypothesis]] predicts the former and has no human evidence for it.Whether immunosenescence is a driver of aging or one of its outputs is unsettled. The answer has practical stakes: it determines whether restoring immune function would extend [[healthspan]] broadly or only reduce infection deaths. The [[geroscience-hypothesis]] predicts the former and has no human evidence for it. The measurement gap is more tractable and more urgent. Without a validated marker, a trial of an immune-restoring intervention has to be powered on clinical infection or vaccine response, which makes it large, slow, and confined to endpoints regulators already accept. The interventions with the best human evidence remain the ones that route around the aged immune system rather than repairing it, and there is no clear reason yet to expect that to change soon.The measurement gap is more tractable and more urgent. Without a validated marker, a trial of an immune-restoring intervention has to be powered on clinical infection or vaccine response, which makes it large, slow, and confined to endpoints regulators already accept. The interventions with the best human evidence still route around the aged immune system instead of repairing it, and nothing yet suggests that will change soon. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
87 lines are the same in both revisions, and 40 of them are not shown. Neither revision here is necessarily the current article — read Immunosenescence for the text this wiki stands behind today.